60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q1 2025 earnings at ($2.81) EPS, Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.53) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, February 19th.

60 Degrees Pharmaceuticals Trading Up 4.7 %

SXTP stock opened at $2.01 on Tuesday. The company’s 50 day moving average is $4.41 and its 200 day moving average is $5.52. The stock has a market cap of $2.96 million, a price-to-earnings ratio of -0.20 and a beta of 4.22. 60 Degrees Pharmaceuticals has a 1-year low of $1.78 and a 1-year high of $35.99.

Insiders Place Their Bets

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 7,164 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $6.35 per share, with a total value of $45,491.40. Following the purchase, the chief executive officer now owns 18,916 shares of the company’s stock, valued at approximately $120,116.60. This trade represents a 60.96 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought a total of 12,073 shares of company stock valued at $76,966 over the last 90 days. Insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.